Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles.

The aim of this work was to study the oral bioavailability in rats of paclitaxel (PTX) when encapsulated as a complex with cyclodextrins in poly(anhydride) nanoparticles (NP). For this purpose three different cyclodextrins were selected: beta-cyclodextrin (CD), 2-hydroxypropyl-beta-cyclodextrin (HPCD) and 6-monodeoxy-6-monoamino-beta-cyclodextrin (NHCD). A single dose of 10mg paclitaxel per kg body weight as PTX-cyclodextrin nanoparticles was used. Plasma curves were characterised by a plateau of paclitaxel concentration close to the C(max) from T(max) till 24h post-administration. For PTX-CD NP and PTX-HPCD NP, these sustained levels of the anticancer drug were found to be between 27 and 33-fold higher than the reported value of drug activity whereas the relative oral bioavailability of paclitaxel was calculated to be higher than 80%. These facts would be directly related with a synergistic effect obtained by the combination of the bioadhesive properties of poly(anhydride) nanoparticles and the inhibitory effect of cyclodextrins on the activity of P-glycoprotein and cythocrome P450.

[1]  Sung-Joo Hwang,et al.  Enhanced Oral Bioavailability of Paclitaxel by Coadministration of the P-Glycoprotein Inhibitor KR30031 , 2004, Pharmaceutical Research.

[2]  C. Porter,et al.  The impact of P‐glycoprotein efflux on enterocyte residence time and enterocyte‐based metabolism of verapamil , 2001, The Journal of pharmacy and pharmacology.

[3]  M. A. Arangoa,et al.  Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[4]  M. Wirth,et al.  Gantrez AN as a new polymer for the preparation of ligand-nanoparticle conjugates. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[5]  J. Beijnen,et al.  Taxanes: a new class of antitumor agents. , 1995, Cancer investigation.

[6]  M. Morris,et al.  Interactions between the flavonoid biochanin A and P-glycoprotein substrates in rats: in vitro and in vivo. , 2010, Journal of pharmaceutical sciences.

[7]  D. Piwnica-Worms,et al.  Effects of cholesterol and enantiomeric cholesterol on P-glycoprotein localization and function in low-density membrane domains. , 2000, Biochemistry.

[8]  Minoru Ishikawa,et al.  Interaction of Modified Cyclodextrins with Cytochrome P-450 , 2005, Bioscience, biotechnology, and biochemistry.

[9]  G. Bonadonna,et al.  Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  T. Kiss,et al.  P-glycoprotein inhibition by membrane cholesterol modulation. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[11]  S. Benita,et al.  Enhanced Oral Absorption of Paclitaxel in a Novel Self-Microemulsifying Drug Delivery System with or Without Concomitant Use of P-Glycoprotein Inhibitors , 2004, Pharmaceutical Research.

[12]  Simon Benita,et al.  Microencapsulation : methods and industrial applications , 1996 .

[13]  G. Giaccone,et al.  A Phase I Safety and Pharmacologic Study of a Twice Weekly Dosing Regimen of the Oral Taxane BMS-275183 , 2007, Clinical Cancer Research.

[14]  J M Irache,et al.  Combined hydroxypropyl-beta-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[15]  J Verweij,et al.  Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. , 2001, European journal of cancer.

[16]  B. Goldspiel.  Paclitaxel Compatibility with Ethylene Vinyl Acetate Bags , 1999, The Annals of pharmacotherapy.

[17]  P. Gao,et al.  Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. , 2003, Journal of pharmaceutical sciences.

[18]  B. Monsarrat,et al.  Taxol metabolism. Isolation and identification of three major metabolites of taxol in rat bile. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[19]  F. Lee,et al.  Preclinical antitumor activity of two novel taxanes , 2000, Cancer Chemotherapy and Pharmacology.

[20]  H. Minderman,et al.  Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. , 2003, Molecular cancer therapeutics.

[21]  W. Couet,et al.  Enhanced Oral Paclitaxel Bioavailability After Administration of Paclitaxel-Loaded Lipid Nanocapsules , 2006, Pharmaceutical Research.

[22]  R. Donehower,et al.  Drug therapy : paclitaxel (Taxol) , 1995 .

[23]  J. Beijnen,et al.  A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer , 2006, British Journal of Cancer.

[24]  E K Rowinsky,et al.  Paclitaxel (taxol) , 1995, The New England journal of medicine.

[25]  R. Lipton,et al.  Phase I clinical and pharmacokinetic study of taxol. , 1987, Cancer research.

[26]  A. Escargueil,et al.  The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Feng,et al.  A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[28]  Hung-Ming Wang,et al.  Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients , 2008, Anti-cancer drugs.

[29]  H. Gréen,et al.  Measurement of paclitaxel and its metabolites in human plasma using liquid chromatography/ion trap mass spectrometry with a sonic spray ionization interface. , 2006, Rapid communications in mass spectrometry : RCM.

[30]  Sushama Talegaonkar,et al.  Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. , 2009, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[31]  J. Nishijo,et al.  Interactions of cholesterol with cyclodextrins in aqueous solution. , 2003, Chemical & pharmaceutical bulletin.

[32]  J. Schellens,et al.  Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration , 2000, Anti-cancer drugs.

[33]  J. Beijnen,et al.  Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[34]  C. Chen,et al.  Enhanced oral bioavailability of paclitaxel by D-alpha-tocopheryl polyethylene glycol 400 succinate in mice. , 2008, International journal of pharmaceutics.

[35]  Der,et al.  Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  B. Leyland-Jones,et al.  Hypersensitivity reactions from taxol. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. McPhail,et al.  Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. , 1971, Journal of the American Chemical Society.

[38]  R. Donehower,et al.  Taxol: a novel investigational antimicrotubule agent. , 1990, Journal of the National Cancer Institute.

[39]  James G. Tarrant,et al.  The discovery of BMS-275183: an orally efficacious novel taxane. , 2003, Bioorganic & medicinal chemistry.

[40]  R. Govindan,et al.  Novel formulations of taxanes: a review. Old wine in a new bottle? , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[42]  J. Schellens,et al.  Oral Delivery of Taxanes , 2001, Investigational New Drugs.

[43]  M. De Brabander,et al.  Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[44]  S. Agelaki,et al.  Treatment of non-small-cell lung cancer with prolonged oral etoposide. , 1998, American journal of clinical oncology.

[45]  J. Irache,et al.  Bioadhesive properties and biodistribution of cyclodextrin-poly(anhydride) nanoparticles. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[46]  Youn-Chul Kim,et al.  Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[47]  J. Schellens,et al.  Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours , 2007, Cancer Chemotherapy and Pharmacology.

[48]  Edwin D. Mares,et al.  On S , 1994, Stud Logica.